RNAi Therapeutics holds more promise than ever in treating many diseases beyond the liver, with momentum in this field growing stronger than ever. Breakthrough companies such as Argonaute RNA and Kate Therapeutics have secured funding to propel their innovative RNAi candidates and delivery platforms, as well as pharma giants partnering with innovative biotech companies to advance RNAi candidates into the clinic.
The 6th RNAi-Based Therapeutics Summit is returning to Boston to showcase the latest delivery technologies, data from clinically successful extra-hepatic targeting, cutting-edge AI tools to assist payload design, and breakthrough chemical modifications that enhance stability, allowing for precise therapeutic delivery.
Uniting 70+ leaders of the RNAi world, this Summit will empower experts to pioneer their RNAi candidates into clinically successful therapies. Bringing together technical and strategic experts from Novo Nordisk, Alynlam, Switch Therapeutics, Aro Biotherapeutics, Novartis, Comanche Biopharma, and more, this meeting is a unique gathering of RNAi’s sharpest minds, dedicated to progressing the next wave of RNAi therapeutics to improve healthcare for patients in need.
Want to learn more? Download our official brochure here: https://ter.li/00r79n